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 Iroquois homeobox gene 3 (Irx3) is a transcription factor belonging to the 
Iroquois family of homeobox genes that is expressed in the embryonic organs of multiple 
organisms. Although much is known about Irx3 during embryogenesis, the cross talk of 
expression and function of Irx3 in peripheral vascular disease (PVD) remains to be 
investigated. Herein, we demonstrate that Endothelial PAS Domain 1 (EPAS1), which is 
involved in vasculogenesis and diseases associated with hypoxia, is an upstream regulator 
of Irx3, and this interaction contributes to the cellular movement of human microvascular 
endothelial cells (HMVECs). Genetic EPAS1 loss-of-function (LOF) studies in HMVECs 
resulted in a reduction of Irx3 mRNA, and Irx3-mediated endothelial cell migration in 
wound healing.  In contrast, the effects of EPAS1 Gain-of-function (GOF) in HMVECs 
showed increased Irx3-mediated endothelial cell migration in wound healing. Taken 
together, these results reveal that Irx3 is an important regulator of cellular movement as a 
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Angiogenesis, the process of new blood vessel growth from pre-existing blood 
vessels, is a natural event that occurs under both normal and pathological conditions.1 
The resulting blood vessel delivers oxygen (O2) and nutrients to all cells within the 
body.2  Thus, O2 levels serve as a key player in the development and subsequent function 
of angiogenesis.3 There are several families of transcription factors that have been 
implicated in angiogenesis regulation, such as the hypoxia inducible factors (HIFs) which 
are stabilized mainly in response to decreased O2 availability, and are responsible for 
most of the transcriptional responses to low O2..
4 Hypoxia-inducible factor (HIF) is a 
transcription factor that responds to changing intracellular oxygen concentration.5 Under 
typical oxygen levels (normoxia), HIF is hydroxylated and acetylated, modifications that 
target the transcription factor for VHL-mediated ubiquitin degradation.5 During hypoxia, 
HIF accumulates and is transported to the nucleus where it induces expression of 
numerous target gene products.5 Secreted growth factors such as Vascular endothelial 
growth factor (VEGF) induce signaling pathways including Phosphoinositide 
phospholipase C gamma, Phosphoinositide 3-kinase, Proto-oncogene tyrosine-protein 
kinase Src, and mothers against DPP homolog 1 (Drosophila) signaling that result in 
endothelial cell proliferation, increased vascular permeability, and cell migration.6 In 





promoting HIF translation.5 Pericytes are also a major player in the angiogenesis 
signaling pathway because they provide structural support for newly formed blood 
vessels, promote endothelial cell survival, guide sprouting vessels, and regulate 
vasoconstriction and dilation.7 This is done through a reciprocal signaling mechanism in 
which PDGF-BB secreted into the matrix by endothelial cells acts as a ligand for PDGF 
receptor-β located on the pericyte membrane. In return, pericytes produce and secrete 
VEGF that signals through the endothelial VEGF receptor. Extracellular matrix proteases 
and regulators induce tissue matrix remodeling in preparation for migration of endothelial 
cells from existing vessels to form new tubing.8 Thus, discoveries that target angiogenesis 
signaling can bring insight to VEGF signaling, the clinical efficacy of VEGF-targeting 
therapies, and potential mechanisms of resistance. Recent studies have identified HIF 
pathways as master regulators of angiogenesis.9 This is due, in part, to low O2 levels, 
which promotes vessel growth by modulating multiple pro-angiogenic signaling 
pathways that mediate key aspects of endothelial cell function.10  
Central to the process of angiogenesis is endothelial cell migration. This process 
is regulated by a stringent equilibrium between pro- and anti-angiogenic molecules.11 
Before propagation of endothelial cells from preexisting vessels can occur the following 
must first take place: the mural cells must be removed; the endothelial cell basement 
membrane must be degraded; and remodeling of the perivascular stroma must take place. 
12 Essential mediators in these processes include Tie2-ligand, serine protease, and matrix 
metallo-proteinases (MMPs).13 Pro-angiogenic factors such as vascular endothelial 





endothelial cells .14 VEGF is the most well studied growth factor in angiogenesis. It is a 
dimeric chemokine protein, and has membership in a family that includes VEGF-A, -B,  
-C, -D, -E, and placenta growth factor (PIGF). There are six molecular isoforms of VEGF 
in humans; VEGF121,-145, -165, -189, -206 (alternatively spliced isoforms of VEGF-A 
15), VEGF-167, and -186 (alternative splice forms of VEGF-B). VEGF121 is the most 
frequent, VEGF165 is the most potent and VEGF189 is the most abundant isoform,16 
making VEGF-A, the best characterized member of homodimeric glycoprotein family.17 
The various isoforms and isotypes of VEGF allows for tissue specific regulation of these 
cellular processes in vivo.18 VEGF-A is a critical component of early vascular 
development. In collaborative studies, it has been shown that mice lacking one VEGF-A 
allele for its receptor have malformed blood vessels leading to embryonic death at day 
10. 19  VEGF-A acts in a dose-dependent fashion to sustain angioblast differentiation and 
survival during early development. After birth however, the vasculature becomes 
independent from VEGF-A.20 The vasculature continues to remain relatively quiescent 
during adulthood, exceptions to this can be seen in the cases of the female reproductive 
cycle,21 would healing, 22 and cancer.23 In the case of cancer, upon signaling from VEGF-
A, the once dormant cells begin the angiogeneic process thus supporting cancer 
progression. During this process, stimulation by a VEGF gradient, results in the 
specification of a leading endothelial cell (EC) called a ‘tip,’ followed by a ‘stalk’ cell 
that trails behind the tip cell; both of which maintain connectivity with the preexisting 
vessel. 24 The constant remodeling of the actin cytoskeleton within endothelial cells into 
lamellipodia, stress fibers, and filopodia is critical to their ability to migrate. 





and are associated with the small hydrolyzed guanosine triphosphate (GTPase) Rat 
sarcoma (Ras)-related C3 botulinum toxin substrate 1 (Rac1) and Actin-related protein 
2/3 (Arp2/3) complexes.25 Stress fibers are actin filaments of opposite polarity connected 
by α-actin.26 Filopodia are membrane projections made up of parallel actin filament 
organized into tight bundles that act as a sensor to motile stimuli.27 Actin-based 
endothelial movement involves protuberance of lamellipodia leading to forward 
extension; the sensing of signals by the filopodia; attachment of protrusions to the 
extracellular matrix (ECM); along with stress-fiber mediated contraction of the cell 
body.25 Once endothelial cells reach an area of decreased vessel density, they arrange in a 
monolayer forming tube-like structures. Lastly, mesenchymal cells in the surrounding 
tissue migrate and proliferate to the adluminal space of the nascent vessels. The 
mesenchymal cells then differentiate into pericytes that stabilize the newly developed 
vessel.28 
Endothelial PAS Domain 1 (EPAS1), also known as Hypoxia inducible factor 2 
alpha (HIF2α), has been well reported as a proangiogenic mediator.29 HIFs require 
heterodimers composed of single copies of α and β-subunits, the latter of which is also 
called the aryl hydrocarbon receptor nuclear translocator (ARNT).30 The mammalian 
genome contains three HIF-genes, HIF-1, HIF-2(also called endothelial Per/ARNT/Sim 
(PAS) domain protein 1 (EPAS1)), and HIF-3,31 that share similar domain structures but 
likely serve non-overlapping physiological roles. Loss of HIF-1α eliminates all oxygen-
regulated transcriptional responses analyzed, suggesting that HIF-1α is dispensable for 
hypoxic gene regulation. In contrast, EPAS1 has been shown to regulate some hypoxia-





lung and other tissues.32 Disruption of the HIF-1α gene induced prominent cardiovascular 
malformations, a lack of organization of the vascular network, and neural tube defects in 
homozygous mice resulting in early embryonic death, whereas inactivation of the HIF-2α 
gene was also lethal but attributed to bradycardia due to a defect in fetal catecholamine 
synthesis or improper remodeling of the primary vasculature during development.33 The 
abundant mRNA expression of EPAS1 in highly vascularized tissues such as the heart, 
lung, placenta, and liver and its hypoxic protein induction suggested a major role in the 
regulation of angiogenesis.31a Hypoxia inducible factor 1 alpha (HIF1α) transactivates the 
EPAS1 gene and encodes a transcription factor involved in the induction of genes 
regulated by local tissue oxygen levels.34 The EPAS1 protein contains a basic-helix-loop-
helix (bHLH) domain, a protein dimerization domain, as well as a common hypoxia 
response element (HRE) sequence found in proteins coding for signal transduction 
pathways that respond to oxygen levels.31a Previous reports demonstrate that EPAS1 
transactivates specific hypoxia-inducible genes such as vascular endothelial growth 
factor-A (VEGF-A).35 EPAS1 forms a heterodimeric complex with the aryl hydrocarbon 
nuclear translocator (ARNT) prior to transcriptional activation of target genes such as 
VEGF-A.34 EPAS1 expression is preferentially expressed in endothelial cells and, unlike 
HIF1α, is capable of specifically activating the transcription of the endothelial tyrosine 
kinase gene Tie2. 31a  
Although previous reports demonstrate EPAS1 is a master regulator of hypoxia-
regulated genes, there are still unknown downstream targets that have not yet been 
investigated.  To date, there have been few studies that have linked Homeobox (Hox) 





differentiation, while emerging data has identified the role of Hox genes in 
cardiovascular development.37 The Iroquois homeobox proteins (IRX 1-6) are a class of 
the Homeobox three amino acid loop extension (TALE) family and are essential in early 
patterning of many embryonic tissues in a spatially and temporally restricted manner. 28-
29, 38 IRX3 has been shown to be involved in the development of the pronephric kidneys, 
the purkinje fibers of myocardium, neurons, lung, and vertebrate kidney.39 Most 
interesting, Irx3 has been identified to be involved in wing development and vein 
formation in drosophila.40 This discovery was the first to suggest that IRX3 may be 
involved in endothelial cell migration, which was confirmed by our own studies that 
revealed IRX3 is responsive to vascular endothelial cell growth factor (VEGF-A) in 
microvascular endothelial cells.41  
Here, we report the novel observation that EPAS1 directly regulates IRX3 function 
under proangiogenic conditions in HMVECs. Chromatin immunoprecipitation (ChIP) 
studies confirm EPAS1 binds to a distal and a proximal site located in the Irx3 upstream 
promoter region. Additionally, EPAS1-mediated Irx3 expression potentiates endothelial 
cell migration in wound healing assays. Strategies to pharmacologically regulate IRX3 
function may provide new therapies to inform ischemic cardiovascular patient treatment 
decisions as well as provide insight into the cancer models that also use angiogenesis to 
metastasize.  
Ischemic Heart Disease (IHD) is a broad term for complications caused by 
narrowed arteries and it is the leading cause of death in the Western world. Angiogenesis 
is the predominant mechanism for increasing collateral blood flow.42 Traditionally, 





surgery, or percutaneous transluminal balloon angioplasty. However, in patients with 
severe diffuse coronary heart disease, revascularization is nearly impossible.43 Thus 
before successful therapeutics can be developed, further elucidation of the molecular 
mechanisms underlying angiogenesis is necessary. Angiogenesis, which is one of the 
seven hallmarks of cancer is required for invasive tumor growth and metastasis, also 
constitutes an important point in the control of cancer progression. Cancer cells initially 
lack angiogenic ability, limiting their aptitude to expand.44 When a tumor begins to 
expand to a point where it needs increased supply of nutrients and oxygen, this creates a 
hypoxic environment. Hypoxia triggers the tumor to release pro-angiogenic factors that 
result in the growth of new blood vessels towards and into the tumor.45 The formation of 
new blood vessels from pre-existing blood vessels (angiogenesis) allows the tumor to 
increase in size. Tumors frequently over express pro-angiogenic factors such as vascular 
endothelial growth factor (VEGF), which allows them to make the switch to the 
angiogenic phenotype;46  making tumor angiogenesis an important therapeutic target.44 
Limitations of traditional cancer therapies are that they do not cause regression of tumors 
that have metastasized to distant cites. The advantage of this study is that anti-angiogenic 
agents can cause production of endothelial cells prove to also cause regression of 
metastatic prostate cells and also prevent their dissemination.47  
 
Purpose of the Study 
The purpose of this study is to investigate the role of EPAS1 as a positive 
transcription regulator of Irx3 expression to promote pro-migratory phenotypes in vitro. 





the temporal expression pattern of EPAS1 and Irx3 in human endothelial cells in response 
to pro- and anti-angiogenic factors such as hypoxia, VEGF-A; (2) utilize both gain and 
loss of function approaches to determine the mechanism by which EPAS1 regulates Irx3; 
and (3) examine the molecular and cellular mechanistic effects of EPAS1 on Irx3 induced 
cellular migration in vitro. Our studies will contribute to the development of therapeutics 
that reveal a novel and unique way in which transcription factors may be utilized in 
human endothelial cells to modulate angiogenesis. 
Statement of the Problem 
Normal angiogenesis is an essential process required for wound healing, restoring 
normal blood flow after injury, and early embryonic development whereas deregulation 
of angiogenesis contributes to the development of many diseases such as ischemia, 
cancer, and arthritis. To date, the Iroquois homeobox transcription factors have not been 
implicated in the angiogenic process and few transcription factors have been identified 
that respond to vascular endothelial growth factor. Herein, for the first time, we will 
demonstrate that Iroquois homeobox 3 in crosstalk with Endothelial PAS domain 1 
effectively modulates angiogenesis in endothelial cells in the presence and absence of 
vascular endothelial growth factor A. Further analysis of EPAS1 revealed it is selectively 
expressed in endothelial cells (EC) and is also involved in angiogenesis and is activated 
by hypoxic conditions. The mechanistic cross talk between the EPAS1 and Irx3 







Migration and Maladies 
Peripheral Vascular Disease 
Peripheral vascular disease (PVD) is a condition in which the blood vessels in the 
lower extremities are narrowed, restricting blood flow.48 Development of PVD is 
characterized by narrowing and occlusion of arterial vessels and eventual reduction in 
distal perfusion by buildup of plaque in blood vessels.49 This plaque is composed of fat, 
cholesterol, calcium, fibrous tissue, and other substances in the blood.50 When plaque 
builds up in the body's arteries, the condition is called atherosclerosis. Over time, 
atherosclerosis can cause hardening and narrowing of the arteries.51 Critical limb 
ischemia is the end stage of lower extremity PVD in which severe obstruction of blood 
flow results in ischemic pain at rest, ulcers, and a significant risk for limb loss causing 
this disease to be a significant contributor to morbidity and mortality.52 Individuals with 
diabetes, high blood pressure, high cholesterol, advanced age, those who smoke or are 
inactive, are at risk for developing PVD. A less common cause of PVD is Buerger 
disease seen in younger individuals.53 Approximately eight to twelve million people in 
the United States currently have peripheral vascular disease. The effects of this disease 





Current treatment goals for PVD should not only focus on disease progression and 
short-term relief but also on the improvement of patient long-term survival.  The standard 
therapy for severe, limb-threatening ischemia is revascularization aiming to improve 
blood flow to the affected extremity.55 If revascularization has failed, or is not possible, 
amputation is often necessary.56 Migration, proliferation, and stabilization of progenitor 
endothelial cells that make up the arteries can lead to PVD treatment alternatives. The 
mechanism underlying arteriogenesis includes the addition and successful migration of 
bone marrow derived monocytes to the perivascular space.57 Proper cellular migration is 
necessary for this form of treatment to be successful. The rationale of hematopoietic stem 
cell/bone marrow cell therapy in PVD is to induce arteriogenesis by enhancing the 
biological restoration process.58 This requires large numbers of functionally active 
precursor cells transferred from the same individual's body, and subsequently, a large 
quantity of bone marrow cells.59 In order to suggest the use of hematopoietic stem 
cell/bone marrow cell therapy in PVD, the bone marrow-derived monocytes must adhere 
to and invade the collateral vessel wall to induce arteriogenesis by boosting the 
physiological repair processes.60 Cellular migration of bone marrow cells is currently 
being investigated as a viable treatment for PVD.61  
Rheumatoid Arthritis 
Migration is a key contributor to the onset of many unfavorable conditions such 
as rheumatoid arthritis (RA). In patients with RA, the synovium is a point of interest. The 
synovium is a thin piece of tissue lining the diarthrodial joint. Under normal conditions, 





with blood vessels sparsely distributed throughout. In RA patients, the structure of the 
synovium drastically changes. The synovium in RA becomes inflamed and increases in 
mass due to hyperplasia of the lining of cells .62  Synovial inflammation in RA is partially 
dependent on migration of inflammatory cells, their retention at the inflammation site, 
and insufficient apoptosis of chronic inflammatory and stromal cells.63  
Proinflammatory cytokines, such as interleukins (ILs) are also key contributors to 
the progression of RA.64  IL-17 has pleiotropic effects on many cell types, induces 
migration of innate immune cells, increases production of cytokines, chemokines, and 
matrix metalloproteases, 65 all of which contribute to the initiation and inflammatory 
phases of RA. Knowledge of these role of migration in RA could lead to a better 
understanding of the mechanism by which the systemic immune response causes local 
joint disorders and will help to provide a molecular basis for therapeutic strategies. 
Endometriosis 
 The migration of human endometrial stromal cells (ESCs) is increasingly 
recognized to contribute to the intense tissue remodeling associated with embryo 
implantation,66 trophoblast invasion67 and endometrial regeneration.68 Coordinated 
migration of ESCs in response to embryonic and trophoblast signals are key to successful 
implantation.69 Migration of ectopic endometrial cells to the eutopic endometrium has 
been documented in an endometriosis mouse model.70 The migrated cells relocated 
primarily to the stroma in the basal layer of the endometrium and their expression profile 
revealed characteristics of cells having undergone epithelial-to-mesenchymal transition.71 





stem-like cells (MSCs) from ovarian endometriomas involves up-regulation of cyclo-
oxygenase 2 (COX-2).72 Interestingly, enhanced Matrix metallo-proteinase (MMP) 
expression, migration and invasion of ectopic ESCs in response to IL-1β can be 
antagonized with an antioxidant and potent inhibitor of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB).73 Migration of ESCs also serves to support 
blastocyst implantation and embryo selection through discriminate motile responses 
directed by embryo quality.71 Harnessing the migratory capacity of progenitor 
mesenchymal stem cells in the endometrium may offer new therapeutic opportunities in 
regenerative medicine. 
Autism 
 Migration is also vital for normal brain development. Dysregulation of migration 
is suggested to be a contributor of autism. Autism is characterized by delayed speech 
development, impaired socialization, and rigid behavior including stereotypic 
movements. 74  In animal models, full-length Aβ precursor protein (APP) functions in 
normal migration of neuronal precursors into the cortical plate during brain development. 
Knockdown of APP inhibits neuronal migration from the cortical ventricular zone to the 
cortical plate in mice.75 Conversely, overexpression of APP accelerates migration of 
neuronal precursor cells into the cortex.75 Therefore, the location of APP at the synapse 
and its developmental function in migration and suppression of cell adhesion support the 
notion that dysregulated levels of APP contribute to brain growth without guidance as 
seen in autism.76  Proliferation, migration, differentiation, myelination, and 





of the known functions of APP in these processes include promotion of proliferation, 
cell–cell adhesion and migration.77  
Angiogenesis 
Endothelial Cell Migration 
Angiogenesis is a process complementary to vasculogenesis during 
development.78 However unlike vasculogenesis, which is the de novo formation of blood 
vessels, angiogenesis is the sprouting of new vessels from preexisting vessels.79 It prunes 
and refines the embryonic vascular network and prompts vessel extension and branching 
to form arterioles, venules, and the broad network of capillaries .80 Central to the process 
of angiogenesis is endothelial cell migration. This process is regulated by a stringent 
equilibrium between pro- and anti-angiogenic molecules.11 Before propagation of 
endothelial cells from preexisting vessels can occur the following must first take place: 
the mural cells must be removed;12c the endothelial cell basement membrane must be 
degraded ;12b and remodeling of the perivascular stroma must take place.12a Key players 
in these processes include Tie2-ligand,13a serine protease,13b and matrix metallo-
proteinases (MMPs).13c Pro-angiogenic factors such as vascular endothelial growth factor 
(VEGF-A), and fibroblast growth factor (FGF) induce migration of endothelial cells.14, 81 
During this process, stimulation by a VEGF-A gradient, results in the specification of a 
leading endothelial cell (EC) called a  ‘tip,’ followed by a ‘stalk’ cells that trails behind 
the tip cell; both of which maintain connectivity with the preexisting vessel.24 The 
constant remodeling of the actin cytoskeleton within endothelial cells into lamellipodia, 





cytoplasmic protrusions that form at the leading edge of migrating cells and are 
associated with the small GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1) and 
Actin-related protein 2/3 (Arp2/3) complexes.25 Stress fibers are actin filaments of 
opposite polarity connected by α-actin.26 Filopodia are membrane projections made up of 
parallel actin filament organized into tight bundles that act as a sensor to motile stimuli.27 
Actin-based endothelial movement thus involves protuberance of lamellipodia leading to 
forward extension; the sensing of signals by the filopodia; attachment of protrusions to 
the ECM; along with stress-fiber mediated contraction of the cell body.25 Once 
endothelial cells reach an area of decreased vessel density, they arrange in a monolayer 
forming tube-like structures. Lastly, mesenchymal cells in the surrounding tissue migrate 
and proliferate to the adluminal space of the nascent vessels. The mesenchymal cells then 
differentiate into pericytes that stabilize the newly developed vessel.28, 83 
Migration in Tumor Progression 
Migration in Lung Cancer 
 Lung cancer is the most common cause of cancer death, both in the United States 
and worldwide.84 According the National Institute of Health, Surveillance, Epidemiology, 
and End Results Program fact sheet on lung cancer, once lung cancer is diagnosed, 
outcomes are poor, with less than 20% of patients surviving 5 years after diagnosis. 
Pleiotrophin (PTN) is a heparin-binding growth factor that is highly expressed in certain 
solid cancers, such as in breast and lung cancers.85 PTN activates its cell surface 
receptors, regulating multiple functions including cell adhesion, cell migration, cell 





migration of lung cancer cells may be an effective method of treating this disease. One 
method to reverse migration in lung cancers is the use of the pharmalogical therapeutic 
Tamoxifen® which is the most thoroughly studied example to date.87 Although an anti-
estrogen medication used for breast cancers, Tamoxifen® has also been shown to lower 
lung cancer mortality. Bouchardy C., et al observed that compared with expected 
outcomes in the general population, lung cancer patients receiving the anti-estrogen 
treatment Tamoxifen® had lower lung cancer mortality .88 This study further supports the 
hypothesis that estrogen therapy modifies lung cancer prognosis by limiting migration of 
the lung cancers cells. 
Migration in Breast Cancer 
According to the American Cancer Society, an estimated 231,840 new cases of 
female breast cancer were diagnosed in 2015. These diagnoses represent 29% of all new 
cancer cases among women. Regrettably, there will also be an estimated 40,290 deaths 
from breast cancer, which represent 15% of all cancer deaths among women. As in the 
case with most cancers, breast cancer becomes lethal once it has metastasized to other 
parts of the body. Therefore, reversing migration of breast cancer cells is also an effective 
therapeutic strategy for this disease.  Researchers have discovered several molecules, 
proteins and environmental factors that contribute to migration of breast cancer cells. For 
example, stress fibers are associated with non-motile cells, while the absence of stress 
fibers is associated with cell migration and tumor invasion. Ras homolog gene family, 
member A (RhoA) and Ras homolog gene family, member C (RhoC) are equally capable 





of the trailing edge during migration.89  In addition to the Ras homolog gene family, 
MicroRNAs (miR), such as miR-125, also been implicated in migration of breast cancer 
cells. Mir-125 has two known isoforms in humans: miR-125a and miR-125b. Altered 
expression of miR-125 has been observed in several malignancies, including breast 
cancer90. The miR-125a and miR-125b were both found to be significantly 
downregulated in breast cancer patients.90b Guo et al explored the role of miRNA-125 in 
breast cancer cells. Overexpressing miR-125a led to decreased in Human antigen R 
(HuR) protein levels, suppressed cell growth, and reduced cell migration and 
proliferation.91 These results suggest that miR-125a can potentially aid in tumor 
suppression in breast cancer by utilizing HuR as a direct and functional target to reduce 
cell migration of breast cancer cells. 
Migration in Prostate Cancer 
 A number of miRNAs have been shown to influence key cellular processes 
involved in prostate tumorigenesis; including cell proliferation, apoptosis-avoidance, and 
migration via the androgen-signaling pathway. MiRNAs have shown differential 
expression in the serum of patients with prostate cancer of varying stages, compared with 
unaffected individuals. Downregulation of miR-145 for example, has been suggested to 
lead to enhanced cell proliferation, migration and invasion in prostate cancer. Fuse and 
colleagues demonstrated that the capacity of PC3 and DU145 prostate cancer cells to 
proliferate, migrate, and invade was impaired by transfection with miR-145.92 MiR-143 is 
also downregulated in prostate cancer, and has been shown in vitro to inhibit proliferation 





homolog (KRAS) expression, thereby inhibiting the EGFR/RAS/mitogen-activated 
protein kinase (MAPK) pathway.93 MiR-13394 and miR-146a95 have also been shown to 
produce similar anti-proliferative, anti-migratory effects in androgen-insensitive prostate 







Human Microvascular Endothelial Cell Culture 
Human microvascular endothelial cells (HMVECs) are an immortalized human 
microvascular endothelial cell line. These cells have been immortalized by transfecting 
them with a PBR-322-based plasmid containing the coding region for the large T antigen, 
the coding region for the simian 40 A gene product.96 These cells were cultured in 
MCDB-131 Medium (Life Technologies, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS), 1% L-glutamine, 0.2% epidermal growth factor (EGF), and 0.1% 
hydrocortisone. Cultures were incubated in 5% humidified CO2 at 37°C in 100-mm 
tissue culture plates. To passage cells, media was aspirated and the monolayer was 
washed once with 1X phosphate buffered saline (PBS). Cells were trypsinized at 37°C 
until detachment was observed. Fresh medium was added to cells to inactivate the 
trypsin. Cells were resuspended and centrifuged for 5 minutes at 2,000 rpm. Cells were 
washed once in 1X PBS and centrifuged again for 5 minutes at 2,000 rpm. Cells were  
passaged every 5 days at 1:3. 
Prostate Cancer Cell Culture 
RWPE-1, LNCaP, DU-145, and PC-3 cells were obtained from  the American 
Type Culture Collection. LNCaP, DU-145, and PC3 cells were maintained in complete  




acids, 1 % antibiotic-antimitotic and 1 % L-glutamine) at 37°C in 5 % CO2 (MediaTech) 
or starvation media (phenol-free RPMI containing 1 % L-glutamine) for 48-hours. 
RWPE-1 was maintained in keratinocyte serum-free medium with supplements (Life 
Technologies) All cells were maintained between 60 % to 80 % confluency. Cultures 
were incubated in 5% humidified CO2 at 37°C in 100-mm tissue culture plates. To 
passage cells, media was aspirated and the monolayer was washed once with 1X 
phosphate buffered saline (PBS). Cells were trypsinized at 37°C until detachment was 
observed. Fresh medium was added to cells to inactivate the trypsin. Cells were 
resuspended and centrifuged for 5 minutes at 2,000 rpm. Cells were washed once in 1X 
PBS and centrifuged again for 5 minutes at 2,000 rpm. Cells were passaged every 5 days 
at 1:3.   
293A Cell Culture 
A subclone of the 293 cell line (human embryonic kidney cells), 293A cells are 
used to facilitate the production, amplification and tittering of replication incompetent 
adenovirus. Minimal essential medium (MEM)-alpha medium (Life Technologies, 
Carlsbad, CA) supplemented with 10% FBS was used to culture the 293A cells. Cells 
were incubated and passaged as described for HMVECs, except cells were passaged 
every 3 days at 1:10.  
Propagation of Cells from Frozen Stocks 
To propagate HMVEC and 293A from frozen stocks, cryotubes were removed 
from liquid nitrogen storage and rapidly thawed in a 37°C water bath. Thawed cells were 




MEM-alpha medium. Cells were incubated in 5% humidified CO2 at 37°C and passaged 
as previously described. 
Generation of Frozen Cells for Long Term Storage 
To prepare frozen HMVEC, RWPE-1, DU-145 or 293A cells, cells were grown to 
80% confluency in 100-mm cell culture dishes. They were harvested by trypsinization 
and washed in 1X PBS. The cells were resuspended in Freezing Medium (Life 
Technologies, Carlsbad, CA) and aliquoted into crytotubes. Cells were frozen at -80°C 
for 24 hours then transferred to liquid nitrogen for long-term storage.  
Addgene Plasmids 
HA-HIF2alpha-pcDNA3 (EPAS1WT) (Addgene plasmid # 18950)97  and HA-
HIF2alpha-P405A/P531A-pcDNA3 (EPAS1P405A/P531A) (Addgene plasmid # 18956)98 
were gifts from William Kaelin. Plasmids were transfected into HMVECs using Xfect 
Transfection Reagent (Clonetech Laboratories, Inc, Mountain View, CA).  24 hours prior 
to  transfection, HMVECs were plated in 1 ml of complete growth medium  and were 50–
70% confluent at the time of transfection. Xfect Polymer was thawed at room 
temperature and thoroughly vortexed before use. In a microcentrifuge tube, 5 μg of 
plasmid DNA was diluted with Xfect Reaction Buffer to a final volume of 100 μl. 
Contents were mixed well by vortexing for 5 seconds at high speed. Plate was incubated 
for 10 min at room temperature to allow nanoparticle complexes to form. Contents were 
spun down for 1 second to collect the contents at the bottom of the tube. The entire 100μl 
of nanoparticle complex solution was added dropwise to the cell culture medium. The 6-




After 6 hours, the nanoparticle complexes were removed from cells by aspiration and 
replaced with 2 ml fresh complete growth medium, and returned to the 37°C incubator. 
Adenovirus Vectors 
Adenovirus vectors Ad.CMV.Irx3-V5, Ad.CMV.Xnull-V5, Ad.CMV.mirIrx3-
eGFP, and Ad.CMV.mirNeg-eGFP were grown in 293A cells, and express high levels of 
the adenovirus type 5 E1A and EB proteins. All constructs were under the control of the 
human cytomegalovirus (CMV) major immediate-early promoter.  
Growth of Viral Stocks 
Adenoviral vectors were grown in 293A cells in Invitrogen’s MEM-Alpha 
medium supplemented with 10% FBS. 293A cells were infected at multiplicity of 
infection (MOI) of 20 and harvested by centrifugation at the time of maximal cytopathic 
effect. Virus was released from 293A cells by lysing with three cycles of freezing in dry 
ice and 90% ethanol and thawing in a 37◦C water bath. Cell debris was pelleted by 
centrifugation and the supernatant was saved and frozen at -80◦C. 
Transduction of Prostate Cancer Cells 
Prior to transduction with adenoviral vectors, DU-145 or RWPE-1 cells  were 
grown to 80% confluency in RPMI complete medium or Keratinocyte complete medium, 
respectively, in 100-mm cell culture dishes. On the day of transduction medium was 
removed and cells were rinsed with 1X PBS. PBS was removed and 5-ml medium was 
added back to each 100-mm culture dish. Adenoviral lysate was added to each 100-mm 
dish at a concentration of 20 MOI. DU-145 or RWPE-1 cells were incubated with the 




100-mm culture dish. DU-145 or RWPE-1 cells were incubated with viral lysate 
overnight at 37◦C. Transduced DU-145 or RWPE-1 cells were used the next day for 
experiments.  
Transduction of Human Microvascular Endothelial Cells 
Prior to transduction with adenoviral vectors, HMVECs were grown to 80% 
confluency in MCDB-131 medium in 100-mm cell culture dishes. On the day of 
transduction medium was removed and cells were rinsed with 1X PBS. PBS was 
removed and 5-ml medium was added back to each 100-mm culture dish. Adenoviral 
lysate was added to each 100-mm dish at a concentration of 20 MOI. HMVECs were 
incubated with the virus for 3 hours at 37◦C. After 3 hours, an additional 5-ml of medium 
was added to each 100-mm culture dish. HMVECs were incubated with viral lysate 
overnight at 37◦C. Transduced HMVECs were used the next day for experiments.  
Transfection of Human Microvascular Endothelial Cells 
Prior to transfection with adenoviral vectors, HMVECs were grown to 80% 
confluency in MCDB-131 medium in 6-well cell culture dishes. On the day of 
transduction medium was removed and cells were rinsed with 1X PBS. PBS was 
removed and 3-ml medium was added back to each culture dish. HMVECs were 
transfected with EPAS1 wild-type plasmid (Addgene plasmid #18950) or An EPAS1 
mutant plasmid, EPAS1P405A/P531A-pcDNA3  (Addgene plasmid #18956), using 
Clonetech® X-fect transfection reagent following manufacture’s protocol. After a six 





HMVECs and PCCs were counted prior to experiments using the Guava Viacount 
assay (Millipore; Billerica, MA).  
Qiagen® Purification of Total RNA 
Total RNA from HMVECs treated with vehicle or 20 ng/ml VEGF-A was 
isolated from HMVECs at various time points using the Qiagen RNeasy® Kit (Valencia, 
CA) following the manufacturer’s protocol. Cell culture medium was aspirated and cells 
were gently washed in 1X PBS. Lysis was performed directly in the 100-mm culture 
dishes using 500 ml of Cell Lysis Buffer. Cells were scraped and the lysate was 
transferred to a QIAshredder spin column and placed in a 2 ml collection tube. The tube 
was centrifuged for 2 minutes at full speed. One volume of 70% ethanol was added to the 
lysate and mixed by pipetting up and down, then 700 µl of the sample was transferred to 
an RNeasy spin column on a vacuum manifold. The vacuum was switched on allowing 
complete transfer of the lysate. This step was repeated until the remaining volume of each 
sample was added to the RNeasy spin column and then 700 µl of Buffer RW1 was added 
to each RNeasy spin column. The vacuum manifold was switched on allowing complete 
transfer of the buffer and 500 µl of Buffer RPE was added to each RNeasy spin column. 
The vacuum was applied allowing complete transfer of the solution. The RNeasy spin 
column were removed from the vacuum manifold and placed inside 2 ml collection tubes. 
The tubes were centrifuged at full speed for 1 minute. Each RNeasy spin column was 




the spin column membrane. The tubes were centrifuged for 1 minute at > 8,000 x g to 
elute the RNA. RNA was stored at -80°C.  
Nanodrop Quantification of Isolated RNA 
The concentration of total RNA was determined by measuring the optical 
absorbance at 260 nm using a Nanodrop apparatus. Sample RNA was used for 
quantification, and DNase/RNase free water was used as a reference.  
Reverse Transcription of Isolated RNA 
RNA was reverse transcribed using Clonetech’s (Mountain View, CA) cDNA 
EcoDry Premix. Briefly, 1 µg of total RNA from each sample was diluted to a final 
volume of 20 µl. Each sample of diluted RNA was added to a tube of EcoDry Premix. 
The samples were mixed by pipetting up and down several times to dissolve the pellet. 
Samples were incubated at 42°C for 60 minutes. The reaction was stopped by heating 
samples at 70°C for 10 minutes. cDNA was stored at -20°C.  
Primer and Oligonucleotide Design 
PCR primers were designed using the Real Time PCR Assay Design Center by 
Roche Applied Science. Primer and oligonucleotides were manufactured by Eurofins 
EWG Operon (Huntsville, AL).  
Real-time PCR sequences used (showed 5’ to 3’): 
1. Irx3 forward primer: CTCTCCCTGCTGGGCTCT 
2. Irx3 reverse primer: CAAGGCACTACAGCGATCTG 
3. EPAS1 forward primer: GAACATTTGGGAAATCTCTTGC 




5. Tie2 forward primer: GAACATTTGGGAAATCTCTTGC 
6. Tie2 reverse primer: CGGAAGAACAATGTAGTCTTTGC 
7. 18s forward primer: GGAAGGGCACCACCAGGAGT 
8. 18s reverse primer: TGCAGCCCCGGACATTCTAAG 
Quantitative Real Time Polymerase Chain Reaction  
qRT-PCR was performed using the SYBR Green I Master Kit (Roche Applied 
Science) with 2.5 µl of cDNA added to 7.5 µl of reaction volume containing 1X master 
mix, 10 µM of forward and reverse primers, and water. Quantitative PCR results from 
each primer pair was normalized to results obtained from the 18s cDNA internal control. 
A linear standard curve was constructed and each sample was run in triplicate. 
Quantification was performed at the log-linear phase, plotted against a serial dilution of 
human reference cDNA with an internal control transcript of 18s cDNA. To determine 
statistical significance a one-way ANOVA and Newman-Keuls test was performed 
comparing treatment groups at each time point to the corresponding treatment at 0 hours 
post-VEGF-A treatment.  
Protein Extraction 
Cells were cultured to 70% confluency in 100-mm cell culture dishes before 
treatment with 20 ng/ml VEGF-A over a 48-hour time course. At each time point media 
was removed from cells and cells were rinsed with 1X PBS and then 150 µl of 
Mammalian Protein Extraction Reagent (Thermo Scientific, Waltham, MA) was added to 
each culture dish which were then placed on a shaker for 5 minutes at room temperature. 




70% ethanol and dry ice for freezing. Once frozen, cells were placed in a 37°C water bath 
to thaw. A total of three freeze-thaw cycles were completed before cells were centrifuged 
at 14,000 x g to pellet debris. The supernatant containing protein was then transferred to a 
new 1.5 ml Eppendorf tube and stored at -80°C.  
Sodium Dodecyl Sulfate Poly-Acrylamide Gel  
Electrophoresis 
 
Protein (13-25 µg) samples were combined with 1 µl of NuPAGE (Life 
Technologies, Carlsbad, CA), Reducing Agent and 2.5 µl of NuPAGE LDS Sample 
Buffer. The volume of each sample preparation was brought to a total volume of 25 µl 
with RNase-free water. Samples were heated at 70°C for 10 minutes in a heat block 
before loading into a pre-cast NuPage 4-12% Bis-Tris gradient gel with SeeBlue Pre-
stained Protein Standard (Life Technologies, Carlsbad, CA). The running buffer used was 
1X 3-(N-morpholino)propanesulfonic-acid (MOPS) buffer at 200 V for 45 minutes.  
Western Immunoblotting 
Protein transfer from precast 4-12% Bis-Tris gels to PVDF membranes was 
performed using the iBlot (Life Technologies, Carlsbad, CA) apparatus according to the 
manufacturer’s protocol. Membranes were blocked for 1 hour at room temperature on a 
rocker with Invitrogen’s Western Breeze Blocking Reagent (Life Technologies, Carlsbad, 
CA) and incubated with a primary antibody solution overnight at 4°C on a rocker. The 
next day, membranes were washed four times with Invitrogen’s Antibody Wash Solution 
and incubated with the Western Breeze anti-species Secondary Antibody Solution for 1 




chemiluminescence and exposed to X-ray film for various lengths of time dependent on 
the protein of interest. 
Antibodies used for Western immunoblot: 
1. Iroquois homeobox protein 3 rabbit polyclonal antibody (Santa Crus, Santa 
Cruz, MA), 1:200 
2.  Endothelial PAS Domain 1 mouse monoclonal antibody (Novus Biologicals; 
San Diego, CA), 1:1000 
3. Phosphor- vascular endothelial growth factor receptor 2 (Tyr1175) rabbit 
monocolonal antibody (Cell Signaling Technology, Danvers, MA), 1:1000 
4.  Phospho- Phosphoinositide-specific phospholipase C gamma 1 (Ser1248) 
rabbit monoclonal antibody (Cell Signaling Technology, Danvers, MA), 
1:1000 
5. Phospho-Src protein tyrosine kinase (Tyr416) rabbit monoclonal antibody 
(Cell Signaling Technology, Danvers, MA), 1:1000 
6. GAPDH antibody (Santa Cruz; Dallas, TX), 1:5000 
The membranes were scanned and  the  photos  were scanned and analyzed with National 
Institute of Health Image J® software in order to obtain densitometry for quantitative  
Prostate Cancer Wound Healing Assay 
RWPE-1 and DU-145 cells were seeded at a high density (1.0X106 cells/ml) in 6 
wells of a 6-well cell culture plate and allowed to adhere overnight in complete medium. 
Cells were then transduced as previously described at a concentration of 20 MOI with the 




V5, Ad.CMV.mirIrx3-eGFP, and Ad.CMV.mirNeg-eGFP. PCAs were incubated with 
virus overnight at 37◦C. The following day, a p-10 pipet tip was used to create a wound 
across each well by scraping the tip from end-to-end. Floating cells were removed by 
washing each well with 1X PBS after scraping. Fresh complete medium was added to 
each well. The wound was monitored over a 48-hour period, with phase contrast and 
fluorescent images taken every 24 hours and rate of closure was quantified by measuring 
the wound area using ImagePro Plus software.  
Human Microvascular Endothelial Cells Wound Healing Assay 
HMVEC cells were seeded at a high density (1.0X106 cells/ml) in 6 wells of a 6-
well cell culture plate and allowed to adhere overnight in complete medium. Cells were 
then transfected and transduced as previously described at a concentration of 20 MOI. 
HMVECs were incubated with virus overnight at 37◦C. The following day, a p-10 pipet 
tip was used to create a wound across each well by scraping the tip from end-to-end. 
Floating cells were removed by washing each well with 1X PBS after scraping. Fresh 
complete medium was added to each well. The wound was monitored over a 48-hour 
period, with phase contrast and fluorescent images taken every 24 hours and rate of 
closure was quantified by measuring the wound area using ImagePro Plus software. 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitaton (ChIP) was performed using the Active Motif 
(Carlsbad, CA) ChIP-It Express Kit and the Covaris Sonicator (Woburn, MA). To 
prepare chromatin, cells were grown to 70-80% confluency and treated with VEGF-A or 




medium was aspirated off the cells and cells were rinsed with 1X PBS. To fix cells 20 ml 
of Fixation Solution containing 37% formaldehyde was added to each plate for 10 
minutes. The fixation reaction was stopped using 10 ml of Glycine Stop-Fix solution. 
Cell Scraping Solution containing 100mM PMSF was added and cells were scraped and 
transferred to 1.5ml Eppendorf tubes. Cells were pelleted by centrifuging for 10 minutes 
at 2,500 rpm then resuspended in 1 ml of ice cold Lysis Buffer and incubated on ice for 
30 minutes. Cells were transferred to a dounce homogenizer and dounced on ice with 10 
strokes to release nuclei. Cells were transferred to a 1.7 ml siliconized microcentrifuge 
tube and centrifuged at 2,400 rpm for 10 minutes at 4°C to pellet the nuclei. The 
supernatant was carefully removed and discarded. The pellets were then resuspended in 
in 1.0 ml of Covaris Wash Buffer and incubated for 10 minutes at 4°C. The 
microcentrifuge tubes were then centrifuged at 1,700 x g for 5 minutes at 4°C. The 
supernatants were removed and the sides of the microcentrifuge tube gently rinsed with 1 
ml of Covaris Shearing Buffer. The microcentrifuge tubes were again centrifuged at 
1,700 x g for 5 minutes at 4°C. The supernatant was carefully removed by pipetting and 
the pellet was resuspended in 520 µl of Covaris Shearing Buffer. Each sample was then 
separated into four 130 µl aliquots containing approximately 3 million cells each. 
Chromatin was sheared using the Covaris Sonicator for 8 minutes per sample according 
to the manufacturer’s operating protocol. After shearing, 10 µl of chromatin was removed 
from each sample (total input) and stored at -20°C.  
The ChIP reaction was set up by adding protein G beads, sheared chromatin, 




ml microcentrifuge tube. For this experiment the primary antibodies used were a EPAS1 
mouse monoclonal antibody (Novus Biologicals; San Diego, CA), an RNA Polymerase II 
control antibody included in the Active Motif ChIP It Express Kit, and IgG2A negative 
control antibody. Tubes were capped, mixed thoroughly and incubated on a rolling shaker 
overnight at 4°C. Tubes were then placed on a magnetic stand to pellet the beads and the 
supernatant was carefully removed and discarded. Magnetic beads were washed four 
times with ChIP Buffer 1, and two times with ChIP Buffer 2. The magnetic beads were 
resuspended in Elution Buffer AM2 and incubated for 15 minutes at room temperature on 
a rotator, and then 50 µl of the Reverse Cross Link buffer was added to elute chromatin 
from the magnetic beads. Chromatin containing supernatant was transferred to a fresh 
tube. The isolated chromatin, as well as the input DNA was incubated at 94◦C for 15 
minutes. Tubes were returned to room temperature and 2 µl of Proteinase K were added 
to the tubes. Tubes were incubated at 37◦C for 1 hour. Tubes were then returned to room 
temperature and 2 µl of Proteinase K Stop Solution was added to each tube. Precipitated 
DNA was then amplified by quantitative PCR using the SYBR Green I Master Kit as 
previously described. The Irx3 primer sequences used were as follows (5’-3’):  









Table 1: EPAS1 Binding Sites on Irx3 Promotor 
DISTANCE FROM     
TRANSCRIPTIONAL  CONSENSUS  


























Data expressed is the average of three technical and/or independent experiments. 
Statistical significance between two groups was calculated using the Student’s T-Test. 
Analyses of more than two groups was calculated using a one-way analysis of variance 
(ANOVA) and a Newman-Keuls post hoc test. A confidence level of <0.05 or <0.001 









We hypothesize that EPAS1 via Irx3 will act as a pro-migratory marker in human 
microvascular endothelial cells (HMVECs). : 
Specific Aim 1 
To identify and validate transcriptional regulators of Irx3 under pro-angiogenic 
conditions.  
Working Hypothesis for Specific Aim 1 
 Irx3 is regulated by transcription factors in response to EPAS1 that alters the 
signaling pathways involved in migration. Furthermore, once activated in response to 
VEGF-A, Irx3 responds to upstream target genes involved in migration such as EPAS1. 
Rationale  
Data from our lab have demonstrated that Irx3 is responsive to VEGF-A; 
therefore, in this aim we will show that Irx3 is expressed in response to other pro-
angiogenic conditions such as hypoxia and this response is essential to EC migration. 
Additionally, in Aim 1 we proposed that in response to VEGF-A, there is increased 





Specific Aim 2 
 To define the temporal expression pattern of Irx3 in human microvascular 
endothelial cells in response to pro-angiogenic conditions. 
Working Hypothesis for Specific Aim 2 
 Irx3 is expressed in endothelial cells in vitro. The expression of Irx3 is modulated 
in a temporal manner in response to pro- angiogenic factors, such as VEGF-A and 
hypoxia. 
Rationale 
 Genetic mapping studies in Drosophila indicate that disruption of caupolican, an 
orthologue of Irx3, results in disorganized wing vein development.40  Furthermore, our 
preliminary data demonstrates: (1) Irx3 expression in human ECs and in mouse ECs in 
the cerebral microvasculature and (2) elevated Irx3 expression in response to the pro-
angiogenic factor VEGF-A. We therefore rationalize that Irx3 is expressed in ECs and the 
expression of Irx3 is regulated by EPAS1 and other factors that govern migration. 
Specific Aim 3 
Use genetic gain- or loss- of EPAS1 function to test the role of Irx3 on the 
migratory potential of endothelial cells.  
Working Hypothesis for Specific Aim 3 
We hypothesize that Irx3 expression is upregulated in the presence of EPAS1 
modulators and is required for endothelial cell migration, a key step in the angiogenic 
cascade. Transient knockdown of EPAS1 will limit Irx3 EC migration, while forced 






It is anticipated that Aim 1 will establish that Irx3 is expressed in human ECs, 
therefore in Aim 3 we will perform functional assays to demonstrate that Irx3 expression 
is not only upregulated in response to VEGF-A and hypoxia, but that Irx3 upregulation 
results in increased EC migration by modulation of EPAS1 expression.  
Specific Aim 4  
Investigate the role of Irx3 in DU-145 prostate cancer cells. 
Working Hypothesis for Specific Aim 4 
We hypothesize that Irx3 expression is required for prostate cell migration, a key 
step in the angiogenic cascade. Transient knockdown of Irx3 will promote cell migration, 
while forced expression of Irx3 will inhibit prostate cancer migratory advantage.  
Rationale 
  It is anticipated that Aim 1 will establish that Irx3 is also expressed in prostate 
cancer cells, therefore in Aim 4 we will utilize genetic Irx3 modifications to perform 
functional assays to demonstrate that Irx3 modulates cell migration 
Specific Aim 1: Identify and Validate Transcriptional Regulators of Irx3  
in Human Microvascular Endothelial Cells 
 
We utilized a siRNA screening approach to identify potential upstream 
transcription regulators of Irx3 expression in HMVECs in response to 12 hours of VEGF-
A stimulation. HMVECs were reverse-transfected in multiwell plates containing two 
validated siRNAs for a single transcription factor. Next, cells were treated with VEGF for 





performed. Analysis of the high-throughput siRNA screen revealed a -30.99 fold 
decrease in Irx3 expression upon siRNA silencing of EPAS1 compared with vehicle-
treated negative siRNA control wells (see Table 2). These results suggest that EPAS1 
functions as an upstream positive regulator of Irx3 expression in  
response to VEGF treatment. 
 














To validate the siRNA screening results, we investigated the effect of gain- or  
loss of function of EPAS1 on endogenous EPAS1 and Irx3 mRNA expression. HMVECs 
were transfected with EPAS1 wild-type plasmid (EPAS1WT), or an EPAS1 transactivation 

























normoxic conditions. Total RNA was harvested, and quantitative RT-PCR was performed 
to determine relative EPAS1 or Irx3 mRNA abundance.  Our results (see Figure 1, #A) 
indicate that compared to the control, the wild type plasmid, EPAS1WT demonstrate a 
significant fold increase for HMVECs mRNA of EPAS1 (20.93-fold ± 0.408, p=0.001). 
In contrast, HMVECs transfected with EPAS1P405A/P531A resulted in less EPAS1 mRNA 
expression than the EPAS1WT of mRNA of EPAS1 (13.44-fold ± 0.594, p=0.001) 
compared to the control group. Our results also indicate EPAS1WT transfected  HMVECs 
resulted a significant increase of Irx3 mRNA (16.44-fold ± 0.108, p=0.002) compared to 
control conditions. In contrast, HMVECs treated with EPAS1P405A/P53A resulted in a 
significant decrease of Irx3 mRNA (1.6-fold ± 0.019, p=0.001) compared to the control. 
These results demonstrate that our transient transfections of EPAS1 successfully 
modulated mRNA of EPAS1 and Irx3 expression in HMVECs. 
EPAS1 bHLH proteins are well known to function as transcription factors 
involved in the induction of genes regulated by oxygen that bind to core DNA sequence 
5’-A/GCGTG-3’ within the hypoxia response element (HRE) of target gene promoters.99 
We identified two putative EPAS1 consensus binding sites; 5’-
AAGCTTCTGCGTGAAGCGCGT-3’ located at -2518 nt (proximal); and 5’-
CGCGCCAAGCGTGTGCGATGG-3’ at -2,653nt (distal) relative to the transcriptional 
start site (see Figure 1, #B). To confirm whether EPAS1 binds the Irx3 promoter directly 
or through an intermediate cofactor, we performed chromatin immunoprecipitation 
(ChIP) experiments to determine EPAS1 binding dynamics in response to VEGF-A (see 
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Figure 1: EPAS1 is a Positive Regulator of Irx3. 
(A) EPAS1 and Irx3 were successfully knocked down in HMVECs using EPAS1 WT 
plasmid or EPAS1P405A/p531A  plasmid and confirmed by QRT-PCR analysis of EPAS1 or 
Irx3. (B) Schematic of the predicted Irx3 binding sites on EPAS1 regulatory regions. (C) 






 MVECs were harvested at 12 hours after VEGF treatment and subjected to 
protein-DNA cross-linking. After immuno-precipitation with anti-EPAS1 or an IgG  
isotype control, DNA fragments were reverse-cross-linked and PCR-amplified with 
primers sets flanking the predicted EPAS1 binding sites in the upstream regulatory region 
of the Irx3 promoter. Primers designed to amplify the sequences for the proximal and 
distal binding sites were used in the quantitative RT-PCR confirmation analysis. 
Additionally, primers designed in an intronic region between exons 3 and 4 of EPAS1 
was used as a negative control. The results indicate that at 12 hours under vehicle 
conditions, chromatin-fold enrichment at the proximal site was 14.16 ± 0.368-fold and 
chromatin-fold enrichment at the distal  site was 13.65 ± 0.241-fold, respectively. Cells 
treated for 12 hours with VEGF resulted in alleviated EPAS1 binding of the Irx3 
promoter with significantly more enrichment (31.79- ± 0.640-fold) at the proximal Irx3 
binding site (p = 0.0028) and 31.08- ± 0.325-fold enrichment at the distal site (p = 0.001) 
compared with vehicle controls. The intronic region of Irx3 showed no significant change 
in fold enrichment under either condition. Taken together, these results indicate that 
EPAS1 is a positive regulator of Irx3 in the presence of VEGF and binds directly to the 
Irx3  promoter. Furthermore, absence of the VEGF ligand partially alleviates EPAS1-
mediated repression of Irx3 in HMVECs.  
Specific Aim 2: To Define the Temporal Expression Pattern of Irx3 in Human 
Microvascular Endothelial Cells in Response to Pro-Angiogenic Conditions 
 
To determine the effect that pro-angiogenic conditions such as VEGF-A100 and 
hypoxia,101 had on Irx3 and EPAS1 gene expression, we treated HMVECs with VEGF-A 





for quantitative RT-PCR. The results indicate that at 12 hours, Irx3 (see Figure 2, #A) 
and EPAS1 (see Figure 2, #C) expression increased significantly 13.04 fold (p = 0.0036) 
and 22.10 fold (p= <0.0001), respectively, post-VEGF-A treatment. Irx3 and EPAS1 
expression increased in a temporal manner from 8–48 h post-VEGF-A treatment 
compared with time-matched vehicle controls. These results also show a reduction in Irx3 
and EPAS1 expression after 48 hours, which is likely due to cells reaching confluency. 
Additionally, endogenous Irx3 expression is elevated in HMVECs in response to VEGF-
A treatment in a temporal manner and peaks in expression at 12 h. Furthermore, Irx3 and 
EPAS1 were decreased as HMVECs reached confluency 48 hours post-VEGF-A 
treatment. Our results also indicate by 48 hours, Irx3 and EPAS1 expression increased 
significantly, 13.83-fold (p = 0.064) and 32.69-fold (p= < 0.0001), respectively, post-
hypoxia treatment with expression as early as 8 hours. Irx3 (see Figure 2, #B) and EPAS1 
(see Figure 2, #D) expression increased in a progressive manner from 8–48 h post-
hypoxia treatment compared with time-matched vehicle controls. These results also show 
a positive correlation between time and hypoxia. Endogenous Irx3 and EPAS1 expression 
are elevated in HMVECs in response to hypoxia treatment in a progressive manner with 
dramatic expression at 48 h. Herein, we are also the first to demonstrate that Irx3 is 
stimulated under hypoxic conditions in vitro and mimics the expression pattern of EPAS1 























Figure 2. Irx3 and EPAS1 mRNA Expression in Response to VEGF-A and Hypoxia. 
 
Specific Aim 3: Test the Role of Irx3 on the Migration of Human 
Microvascular Endothelial Cells 
 
To demonstrate effective gain of function of EPAS1 expression, HMVECs were 
transfected with EPAS1 plasmids as previously described. To study the effect of EPAS1 
gain of function on Irx3-induced cell migration, HMVECs were transfected with EPAS1 
wild-type plasmid  once they were~80% confluent in a six well plate. After a six hour 





with recombinant adenoviral vectors containing a CMV immediate-early promoter 
(CMV-IE), human Irx3 cDNA (BC023667.2)/tag on demand V5 epitope (Ad.CMV.Irx3-
v5 and Ad.CMV.Xnull-v5), CMV-IE/mirIrx3/eGFP, or synthetic scrambled control 
miRNA (Ad.CMV.miIrx3-eGFP and Ad.CMV.miNeg-eGFP) (m.o.i. = 20) for 12 hours 
in complete media. A wound was made in each well and cells were allowed to migrate 
for 12 hours. Results indicate that cells transfected with EPAS1 WT and transduced with 
Ad.CMV.Irx3-v5 resulted in increased wound healing as early as 12 hours compared with 
the Ad.CMV.Xnull-v5 control vector. In contrast, HMVECs transfected with EPAS1 WT 
and transduced with Ad.mirIrx3-eGFP exhibited markedly reduced migration at 12 hours 
compared with the negative control vector Ad.mirNeg-eGFP  (see Figure 3, #A). 
Temporal assessment of the wound area in HMVECs, transfected with EPAS1 WT and 
transduced with the Ad.mirIrx3-eGFP, indicate an area of 32.50 ± 0.707% at 12 hour 
versus control vector Ad.mirNeg-eGFP-transduced cells (53.5 ± 2.121%). Additionally, 
cells transfected with EPAS1 WT and transduced with Ad.CMV.Irx3-v5 resulted in 
increased wound healing as early as 6 hours compared with the Ad.CMV.Xnull-v5 






























Figure 3: Gain of Function of EPAS1 Modulates the Irx3 Endothelial Cell Migratory 
Potential. 
(A) Closure of wound area of HMVEC using HMVECs transfected with EPAS1WT 
Plasmid and Irx3 viral vectors. (B) Quantitative analysis of HMVEC migration obtained 






To demonstrate effective loss of function of EPAS1 expression, HMVECs were 
transfected with EPAS1 plasmids as previously described.  To study the effect of EPAS1 
loss of function on Irx3-induced cell migration, HMVECs were transfected with 
EPAS1P405A/P531A and transduced with Irx3 adenoviral vectors as previously described A 
wound was made in each well and cells were allowed to migrate for 12 hours. Results 
indicate that cells transfected EPAS1P405A/P531A and transduced with Ad.CMV.Irx3-v5 
resulted in decreased wound healing as early as 12 hours compared with the 
Ad.CMV.Xnull-v5 control vector additionally, cells transfected with EPAS1P405A/P531A 
and transduced with Ad.mirIrx3-eGFP exhibited markedly reduced migration at 12 hours 
compared with the negative control vector Ad.mirNeg-eGFP (see Figure 4, #A). 
Temporal assessment of the wound area in HMVECs, transfected with EPAS1P405A/P531A 
and transduced with all of the Irx3 recombinant viral vectors Ad.mirIrx3-eGFP did not 
result in closure of the wound even after 12 hours versus control vector. This data 
indicate that EPAS1 gain of function or loss of function can regulate Irx3 modulation of 
wound closure rates in HMVECs and suggest a functional role of EPAS1 in mediating 



















Figure 4. Loss of Function of EPAS1 Modulates the Irx3 Endothelial Cell Migratory  
Potential. 
(A) Closure of wound area of HMVEC using HMVECs transfected with EPAS1P405A/p531A plasmid 







Specific Aim 4: Investigate the Role of Irx3 in Du-145 Prostate Cancer Cells 
Cistrome studies from Specific Aim 1 identified transcription factors involved in 
cellular death, survival, and movement in DU-145 cells. CITED2 is identified as a 
downstream target of Irx3 in DU-145 cells (see Table 3).  









A previous study identified hypermethylation of the 5′ CpG island region of the 
homeobox gene Irx3 in TRAMP.102 The aforementioned study utilized LNCaP cells. 
Table 4 compares several prostate cancer cell lines which includes their metastatic 
behavior.103 Herein, we observe that LNCaP does not metastasize to the bone whereas 
other cell lines, such as DU-145, do have metastatic potential. We therefore rationalize 
that Irx3 is differentially expressed in prostate cancer cell lines and the expression of Irx3 
















To investigate the expression patterns  of  Irx3 in prostate cancer cell lines, 
western blotting was performed using protein obtained from primary cultures  of   human 
prostate  epithelial  cells, RWPE-1, and human  prostate cancer  cells  LNCaP, DU-145, 
and PC-3 (see Figure 5).  Previous data from our lab identified that human microvascular 
endothelial cells (HMVECs) expressed high levels of Irx3 when exposed to 12 hours of 
VEGF-A41 therefore we used HMVECs as a positive control for Irx3 expression in this 
panel. Elevated protein expression of Irx3 can be seen in HMEC-1, RWPE-1 and DU-145 







































Irx3 61 kDa 
 
 
GAPDH 37 kDa 
 









Figure 5.  Irx3 Protein is differentially expressed in panel of prostate cancer cell lines. 
 
Densitometry data from the western blot reveals that Irx3 protein levels are 
significantly decreased in LNCaP (0.2-fold ±0.087, p=0.002) and PC3 (0.3-fold ±0.093, 












Figure 6. Densitometry of Figure 5 Irx3 protein is differentially expressed in panel of 









































HMVEC RWPE-1   LNCaP     DU-145     PC-3 
Complimentary DNA obtained was analyzed using Quantitative Polymerase 
Chain Reaction. Analysis of mRNA from HMEC-1, RWPE-1, LNCaP, DU-145, and PC-
3 reveal that expression of Irx3 is significantly decreased in LNCaP and PC-3 cells 






Figure 7.  Irx3 mRNA is differentially expressed in a panel of prostate cancer cell lines. 
 
RT-PCR was performed with the cDNA obtained from Figure 3, which reveals 


















GAPDH 37 kDa 
Recombinant adenoviral vectors were designed as previously described41. RWPE-
1 cells were transduced in normal growth medium with the indicated adenovirus for 12 
hours. Whole cell lysate were collected and ran on a western blot which reveals that there 
is higher expression of Irx3 transduced with Ad.CMV.Irx3-v5 and there is less expression 
of Irx3 in both the Ad.mirIrx3-eGFP and its control Ad.mirNeg-eGFP  in RWPE1 (see 
Figure 9). Densitometry data from the western blot reveals that Irx3 levels  significantly 
increase in cells treated with Ad.CMV.Irx3-v5 and significantly decrease upon treatment 


























































Figure 10. Densitometry of Figure 9 Irx3 successfully transduced in RWPE-1 cell 
lysates. 
 
Similarly, DU-145 cells were transduced in normal growth medium with the 
indicated adenovirus for 12 hours. Whole cell lysate were collected and ran on a western 
blot which reveals that there is higher expression of Irx3 transduced with Ad.CMV.Irx3-
v5 and there is less expression of Irx3 in both the Ad.mirIrx3-eGFP and its control 
Ad.mirNeg-eGFP in DU-145 (see Figure 11). Densitometry data from the western blot 
reveals that Irx3 levels significantly increase in cells treated with Ad.CMV.Irx3-v5  and 
significantly decrease upon treatment with Ad.mirIrx3-Egfp  and its control Ad.mirNeg-








Irx3 61 kDa 
 
 
































































Complimentary DNA obtained from RWPE-1 and DU-145 treated with the gain 
and loss-of-function Irx3 and their controls reveals that there is a ~20 fold increase of 
Irx3 in cells treated with Ad.CMV.Irx3-v5 compared to its control Ad.CMV.xnull-v5 
(see Figure 13, #A). There is a ~0.5 fold decrease of Irx3 expression in Ad.mirIrx3-eGFP  












Figure 13: Quantitative RT-PCR analysis of Irx3 expression after transduction with the indicated 



















































The effect of Irx3 gain- and loss-of function on cell motility was assessed by 
wound healing assays RWPE-1 (see Figure 14) and DU-145 (see Figure 15) were 
transduced with recombinant adenoviral vectors. Twenty-four hours after the wound, the  
non-transduced RWPE-1 cells had an open wound area of 57%, Ad.CMV.Irx3-v5 had an 
open wound of 76% and Ad.mirIrx3-eGFP 61%. At 72 hours non transduced RWPE-1 













Figure 15: Quantitative data of Wound Healing Assay of RWPE-1 cells transduced with 





This similar trend is seen in DU-145 cells. At 24 hours the  non-transduced DU- 
145 cells had an open wound area of 29%, Ad.CMV.Irx3-v5 had an open wound of 52% 
and Ad.mirIrx3-eGFP 28%. At 72 hours non-transduced DU-145 cells had an open 
wound area of 3%, Ad.CMV.Irx3-v5 had an open wound of 16% and Ad.mirIrx3-eGFP 
1%.  Transduction of RWPE-1 and DU-145 with gain-of-function Irx3 did not 
completely close the wound area even after 72 hours. In contrast, the cell lines transduced 
with loss of Irx3 function closed the wound area at a faster rate in RWPE-1 (see Figure 
16) and DU-145 (see Figure 17) cell lines over a 72 hour period. These data indicates that 
Irx3 loss-of-function can modulate wound closure rates of RWPE-1 and DU-145 cells 























Figure 17. Quantitative data of Figure 16 Wound Healing Assay of RWPE-1 transduced 
with Irx3 Adenoviral Vectors. 
 
Discussion 
Migration of endothelial cells is a key component in the series of molecular and 
cellular events that occur during angiogenesis.104 Many previous studies illustrate 
essential signaling pathways that are essential for angiogenesis, there remains a lack of 
insight regarding transcription regulatory networks that govern EC migration and cell 
fate. 105 Homeobox genes are characterized as early mediators of fetal patterning and 
development .106  IRX3 functions as an early facilitator of transcription signaling which  
targets specific genes during normal embryogenesis.107 In the context of angiogenesis, 





(HIFs).108 Our siRNA screening studies identified EPAS1 as a transactivator of Irx3 
expression in response to VEGF-A treatment. Activation of VEGF receptors contribute to 
ECs migration and proliferation during angiogenesis and lymph-angiogenesis.109 It has 
been demonstrated that genetic or pharmacological strategies to manipulate EPAS1 
expression can severely disrupt angiogenesis via the VEGF receptor.34, 110 It is also 
important to note that VEGF does not directly activate EPAS1, but instead EPAS1 
transactivates the VEGF ligand promoter under hypoxia via HIF-1-binding and is 
enhanced markedly by cotransfection with ARNT.111 
Our ChIP studies confirmed the results of our siRNA screen, demonstrating that 
EPAS1 binds to the Irx3 promoter with increased -fold enrichment in the presence of 
VEGF. In response to VEGF ligand, we observed binding enrichment at the classical 
bHLH EPAS1 binding sites located in the upstream regulatory region. EPAS1 is a known 
trans-activator of hypoxic-inducible genes that promote angiogenesis. Our data suggest 
that EPAS1 transactivates Irx3 by binding the classical bHLH EPAS1 binding site that 
may also involve HIF-dependent cofactor association in the Irx3 promoter region. Future 
experiments to decipher the mechanism through which EPAS1 directly regulates Irx3 
expression during angiogenesis and the interaction with Notch signaling mediators, and 
cofactors are required. 
After we confirmed that EPAS1 is a positive regulator of Irx3 we investigated the 
temporal expression of Irx3 in endothelial cells in response to known EPAS1 effectors; 
VEGF and hypoxia stimulation. Our findings indicate that Irx3 and EPAS1 are expressed 





treatment, and that it is maintained over a period of 48 h. This correlates to a decrease in 
Irx3 and EPAS1 mRNA expression when cultured HMVECs become confluent 48 h after 
VEGF-A treatment. Our results also indicate by 48 hours, Irx3 and EPAS1 expression 
increased significantly post-hypoxia treatment with expression as early as 8 hours. Irx3 
and EPAS1 expression increased in a progressive manner from 8–48 h post-hypoxia 
treatment compared with time-matched vehicle controls. These results also show a 
positive correlation between time and hypoxia. These results demonstrate that 
endogenous Irx3  and EPAS1 expression are elevated in HMVECs in response to hypoxia 
treatment in a progressive manner with dramatic expression at 48 h. Our results agree 
with others that EPAS1 is expressed in endothelial cells.31a Although Irx3 behaved in a 
similar manner as EPAS1, greater insight is needed to identify downstream Irx3 
transcription targets in the endothelium of the vasculature and perform metadata analyses 
to decipher common and specific gene targets of IRX proteins in endothelial cells in 
response to hypoxia in a strict manner. 
IRX genes have been identified and conserved in human, mice and an array of 
other species.112 Synonymous IRX proteins have been identified in drosophila. Early 
reports in Drosophila describe the requirement of the IRX proteins Araucan (Ara) and 
Caupolican (Caup) for proper wing vein formation. Loss of L1-L5 wing vein formation 
was observed when the loci of the Ara and Caup were disrupted.40, 113 We previously 
reported that transient knockdown of endogenous Irx3 in HMVECs suppressed VEGF-
induced cell migration during wound closure and chemotactic migration, whereas 





chemotaxis .41 These data demonstrate that in the presence of EPAS1, IRX3 accelerated 
migration of HMVECs, whereas, a transactivation mutation of EPAS1 partially abrogated 
the ability of IRX3 to promote cell migration. The EPAS1 transactivation mutant contains 
mutations at Proline 405 to Alanine and Proline 531 to Alanine, which leads to loss of 
DNA-binding capability. The results of the migration assays are particularly interesting 
because directional migration is critical for angiogenesis during fetal development. 114 
Here, we show that EPAS1 is an upstream proangiogenic transcription regulator of Irx3 
and functions to promote endothelial cell migration s essential to productive 
angiogenesis.  
We demonstrate that IRX3 may be utilizing the Src signaling pathway. Herein, we 
report that IRX3 partially promotes EC migration via activation of the Src signaling 
pathway. Previous reports have indicated that Src activation promotes survival, 
migration, and invasion pathways.115 Many transmembrane proteins have been identified 
that can activate the Src pathway such as adhesion receptors, receptor tyrosine kinases, 
G-protein coupled receptors and cytokine receptors.116 We posit that in our model system 
transcription activation of Irx3 promotes EC migration via the Src pathway that can be 
accentuated by EPAS1, however rigorous studies need to be performed to delineate the 
precise mechanism.  
In addition to the work we conducted using endothelial cells our ChIP-on-ChIP 
data also revealed that Irx3 may also play a role in prostate cancer cell migration. Prostate 
cancer is the second most frequently diagnosed cancer in men worldwide, the sixth 





remains an important public health concern in Western countries and an emerging 
malignancy in developing nations.118  Relative high rates of prostate cancer has also been 
found in developing areas such as the Caribbean, South America and sub-Saharan Africa, 
while the lowest rates are found in South-Central Asia. Prostate cancer is the leading 
cause of cancer and the second leading cause of morbidity in men in North America. 
African American men have the highest incidence and mortality rates as compared with 
Caucasian men and present with more aggressive disease at the time of diagnosis. 
However, the information is very limited on the role of Irx3 in prostate cancers.  
Extensive scientific evidence indicates that hox genes are critical for 
morphogenesis, organogenesis and differentiation, 37b-d while emerging data has 
identified the role of hox genes in tumor development.119 Iroquois homeobox genes (Irx) 
are a member of the Homeobox (HOX)-Three Amino acid Loop Extension (TALE) 
family of genes and are essential in early patterning of many embryonic tissues in a 
spatially and temporally restricted manner. 38 Several Irx members have shown to be 
involved in carcinogenesis. For example, Irx1 acts as a tumor suppressor gene in gastric 
cancers; 120 Irx3 has been shown to be down-regulated in LNCaP cells; 121 Irx4 has been 
shown to suppress prostate cancer growth in benign prostatic hyperplasia and prostate 
cancer genome wide association studies; 122 and Irx5 regulates cell cycle and apoptosis in 
human prostate cancer patient samples. One study has reported that hypermethylation of 
the 5′ CpG island region of the homeobox gene Irx3 in TRAMP is associated with 
reduced gene expression which allowed TRAMP to have conditions reminiscent of 





cancer progression and the expression and function of Irx3 in human cancers remains to 
be investigated. 
Herein we have shown the expression profile of Irx3 in normal and prostate 
cancer cell lines reflecting its expression in normal and disease states of varying stages. 
We report that significant expression of Irx3 is present in normal prostate epithelial cells 
as well as moderately aggressive prostate cancer cell, DU-145. LNCaP cells have been 
categorized as a prostate cancer cell line that is androgen sensitive with low 
tumorigenicity,123 whereas DU-145 and PC-3 are both androgen sensitive with moderate 
and high tumorigenicity, respectively. 124 Our findings agree with others that Irx3 has low 
expression in LNCaP cells, however we are the first to identify the protein and mRNA 
levels of Irx3 in RWPE-1, DU-145 and PC-3 cell lines. Further studies will need to be 
conducted to identify the potential relationship between Irx3, androgen and its receptor.  
Prostate cancer metastasis is a complex and vigilant process of events of which 
cellular migration is involved. 125 Numerous studies have identified the importance of 
migration in prostate cancer metastasis, 126 however greater insight is needed on the role 
of Hox genes that regulate prostate cancer migration. Therefore, we investigated the 
functional significance of Irx3 in DU-145 prostate cancer cells. Upon successful 
transduction of gain- and loss- of Irx3 function in the cells, our findings Irx3 plays a role 
in cell migration. Gain of Irx3 function decreased cell migration in both RWPE-1 and 
DU-145 cell lines. Once Irx3 function was knocked down, cells migrated at a faster rate 
than compared to the non-transfected cell lines. Other reports in Drosophila have 





with migration.127 In the present study we have also identified that Irx3 plays a vital role 
in DU-145 and RWPE-1 cellular movement.  
It is believed that part of the reason prostate cancer is so widespread in developed 
countries is due to increased practice of prostate specific antigen (PSA) testing and 
subsequent biopsies. Recent discoveries have attributed cancer therapeutics to an onset of 
cardiovascular disease.128 For example, a recent report indicated that androgen 
deprivation therapy (ADT), which is suggested to prostate cancer patients to reduce 
levels of male hormones, was linked to triple the risk of heart-related death in men with 
heart failure or in those who had a previous heart attack.129 
In summary, the present study has provided direct evidence of the vital role of 
Irx3 in DU- migration of these cells. The varying levels of Irx3 in endogenous protein 
and mRNA levels of our prostate cell panel also supports the inclusion of Irx3 in a tissue- 
or urine based cancer biomarker panel to inform prostate cancer patient treatment 
decisions.  Irx3 over expression has been shown to decrease prostate cell migration while 
knock down of Irx3 had opposite effects. Strategies to pharmacologically regulate Irx3 






 The present study has provided direct evidence of the vital role of Irx3 in prostate 
cancer and endothelial cell migration of these cells. The varying levels of Irx3 in 
endogenous protein and mRNA levels of various cell lines also supports the inclusion of 
Irx3 in a tissue- or urine based biomarker panel to inform cancer or cardiovascualr 
patient treatment decisions.  Irx3 over expression has been shown to decrease prostate 
cell migration and while knock down of Irx3 had opposite effects. Strategies to 
pharmacologically regulate Irx3 function in moderately metastatic prostate cancer cells 
may provide for new therapies.  Additionally, our findings describe a novel functional 
role of Irx3 as a proangiogenic mediator of EPAS1and hypoxia signaling by promoting 
EC migration. Taken together under hypoxic condition these results indicate that Irx3 is 
a downstream target of EPAS1 signaling to promote migration in HMVECs or ablate 
migration of DU-145 cells via CITED2 (see Figure 18). Therefore, strategies to 
pharmacologically regulate Irx3 function may provide new therapies to inform prostate 

















Figure 18.  Schematic of EPAS1 Mediated Irx3 Cell Migration in PCa and HMVEC. 
 
Future Directions 
In this study we elucidated a mechanism by which Iroquois homeobox gene 3 
(Irx3) regulates angiogenesis through EPAS1 signaling in response to VEGF-A and 
hypoxic conditions. Each experiment discussed in this study was performed in vitro using  
human prostate epithelial, transformed prostate epithelial, or microvascular endothelial 
cells in culture. Thus, the future directions of this project involve the expansion of this 
work into in vivo model systems. In vivo studies would be more insightful in showing 
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